- Home
- CSTL
as 07-26-2024 4:00pm EST
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 586.9M | IPO Year: | 2019 |
| Target Price: | $31.00 | AVG Volume (30 days): | 396.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.07 - $25.91 | Next Earning Date: | 08-05-2024 |
| Revenue: | $250,725,000 | Revenue Growth: | 64.71% |
| Revenue Growth (this year): | 20.91% | Revenue Growth (next year): | 0.28% |
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Oelschlager Kristen M | CSTL | Chief Operating Officer | Jul 1 '24 | Sell | $21.22 | 2,793 | $59,278.63 | 148,618 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.39 | 2,328 | $54,456.58 | 57,933 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.39 | 1,192 | $27,883.26 | 82,502 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.39 | 1,192 | $27,883.26 | 71,399 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.39 | 380 | $8,888.96 | 8,533 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.39 | 380 | $8,888.96 | 8,531 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.39 | 380 | $8,888.96 | 8,531 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.39 | 380 | $8,888.96 | 8,531 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.98 | 40 | $959.16 | 57,893 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.98 | 20 | $479.58 | 82,482 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.98 | 20 | $479.58 | 71,379 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.98 | 6 | $143.87 | 8,527 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.98 | 6 | $143.87 | 8,525 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.98 | 6 | $143.87 | 8,525 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jun 3 '24 | Sell | $23.98 | 6 | $143.87 | 8,525 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | May 14 '24 | Sell | $24.17 | 2,085 | $50,402.79 | 60,544 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | May 14 '24 | Sell | $24.17 | 1,067 | $25,793.66 | 83,839 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | May 14 '24 | Sell | $24.17 | 1,067 | $25,793.66 | 72,736 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | May 14 '24 | Sell | $24.17 | 340 | $8,219.16 | 8,959 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | May 14 '24 | Sell | $24.17 | 340 | $8,219.16 | 8,957 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | May 14 '24 | Sell | $24.17 | 340 | $8,219.16 | 8,957 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | May 14 '24 | Sell | $24.17 | 340 | $8,219.16 | 8,957 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | May 14 '24 | Sell | $24.95 | 283 | $7,060.57 | 60,261 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | May 14 '24 | Sell | $24.95 | 145 | $3,617.61 | 83,694 | SEC Form 4 |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | May 14 '24 | Sell | $24.95 | 145 | $3,617.61 | 72,591 | SEC Form 4 |
Latest Castle Biosciences Inc. News
CSTL Breaking Stock News: Dive into CSTL Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Investors in Castle Biosciences (NASDAQ:CSTL) have unfortunately lost 71% over the last three years
Zacks
4 days ago
Zacks Market Edge Highlights: Soundhound AI, Afya, Castle Biosciences, TriMas and Immersion
Business Wire
5 days ago
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
Zacks
7 days ago
5 Top Small Cap Stocks to Buy Now
Business Wire
12 days ago
Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
Zacks
14 days ago
All You Need to Know About Castle Biosciences (CSTL) Rating Upgrade to Strong Buy
Business Wire
16 days ago
Castle Biosciences Honored with Top Workplaces Awards
Business Wire
a month ago
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
Compare CSTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.